Table 2

Characteristics and laboratory values of children registered to the Finnish Paediatric Diabetes Registry in the Helsinki University Hospital district during the pandemic period (1 April–31 October 2020) and during corresponding prepandemic periods in 2016–2019

Prepandemic periods
2016–2019
(n=231)
Pandemic period
2020
(n=84)
P value
Number of patients per period, n57.75*84
Incidence, per 100 000 person-years (95% CI)38.68 (34.00 to 44.00)56.00 (45.22 to 69.34)0.004
Age, median (IQR), years8.0 (4.0–11.9)8.2 (4.4–11.2)0.53
Female sex, n (%)103 (45)36 (43)0.80
Previously healthy, n (%)†215 (93)74 (88)0.17
Duration of symptoms, n (%)
 less than 7 days39 (18)18 (22)0.29
 7–13 days70 (32)24 (30)
 14–20 days34 (15)14 (18)
 21–27 days28 (13)12 (15)
 28 days or more51 (23)12 (15)
Admitted to PICU, n (%)15 (6)16 (19)0.002
Severe DKA (blood pH <7.10), n (%)20 (9)13 (16)0.10
Laboratory values
pH, median (IQR)7.36 (7.25–7.39)7.36 (7.18–7.39)0.34
β-hydroxybutyric acid, median (IQR), mmol/L3.1 (0.7–6.0)4.5 (0.9–6.1)0.23
Glucose, median (IQR), mmol/L25.8 (18.9–34.3)23.4 (18.0–29.9)0.04
HbA1C, median (IQR), mmol/mol104 (84–129)103.0 (82–119)0.46
HbA1C, median (IQR), %11.7 (9.9–14)11.6 (9.7–13.0)0.46
  • *Mean number of patients per study period during prepandemic study periods 2016–2019.

  • †No underlying chronic medical conditions requiring medication or ongoing medical attention present at the time of T1D diagnosis.

  • DKA, diabetic ketoacidosis; HbA1C, glycated haemoglobin; PICU, paediatric intensive care unit; T1D, type 1 diabetes.